Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis

Journal of Pathology

Volumn 187, Issue 3, 1999, Pages 295-301

  Hao, Xingpei ^a   Bishop, Anne E ^b   Wallace, Marina ^a   Wang, Hong ^a   Willcocks, Teresa C ^d   Maclouf, Jacques ^c   Polak, Julia M ^b   Knight, Stella ^a   Talbot, Ian C ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Hôpital Lariboisière ^*

Author keywords

Carcinogenesis; Colorectum; Cox 2; Immunohistochemistry; RT PCR

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; KI 67 ANTIGEN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOMA; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INTESTINAL MUCOSA; ISOENZYMES; MEMBRANE PROTEINS; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 0032920064     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199902)187:3<295::AID-PATH254>3.0.CO;2-Y     Document Type: Article

References (58)

1. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-4404.
2. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. A Engl J Med 1991; 325: 1593-1596.
3. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-358.
4. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327.
5. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 1993; 307: 285-287.
6. Sub O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-1177.
7. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Halle R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group, J Natl Cancer Inst 1993; 85: 912-916.
8. Giovannucci E, Rimm RB, Stampfer MJ, Colditz GA, Ascherio A, Willette WC. Aspirin use and the risk for colorectal cancer and adenomas in male health professionals. Ann Intern Med 1994; 121: 241-246.
9. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 63-5639.
10. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316.
11. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Fillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-1619.
12. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Cotorectal Dis 1993; 8: 13-17.
13. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyps occurrence in patients with familial adenomalous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-366.
14. Reddy BS, Naymi J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990; 50: 2562-2568.
15. Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumours in the rat. Arch Surg 1991; 126: 1094-1096.
16. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16-alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991; 51: 4528-4534.
17. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-1497.
18. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-1472.
19. Marnett LJ. Aspirin and potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589.
20. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-F191.
21. Coll PJ, Garavito RM. The isoforms of cyclooxygenase: structure and function. Expert Opin Invest Drugs 1994; 3: 1171-1180.
22. Battistini B, Botting R, Bakhle YS. Cox1 and Cox2: toward the development of more selective NSAIDs. Drug News Perspect 1994; 7: 501-512.
23. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein. Cancer Res 1995; 55: 2556-2559.
24. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789.
25. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
26. Gustafson-Svärd C, Lilja I, Hullböök O, Sjödahl R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonie tumours in rats. Gut 1996; 38: 79-84.
27. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomos. Gastroenterology 1996; 111: 1134-1140.
28. Boobol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumour formation are blocked by sulindac in a murine model of familial adenomatous polyposss. Cancer Res 1996; 56: 2556-2560.
29. A718 knockout mice by inhibition of cyclooxygenase 2 (Cox2). Cell 1996; 87; 803-809.
30. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998:58: 409-412.
31. Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygecase-2. J Biol Chem 1993; 268: 23 448-23 454.
32. Hukkanen M, Corbett SA, Batten J, et al. Aseptic loosening of total hip replacement. J Bone Joint Surg (Br) 1997; 79B: 467-474.
33. Du MQ, Singh N, Husseuin A, Isaacson PG, Pan LX. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT). J Pathol 1996; 178: 379-384.
34. Ristimäki A, Honkanen N, Jänkalä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280.
35. Otori K, Oda Y, Sugiyama K, et al. High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut 1997; 40: 660-663.
36. Zhu D, Keohavong P, Finkelstein SD, et al. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997; 57: 2485-2492.
37. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res 1997; 57: 3465-3470.
38. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710-714.
39. Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 1987; 28: 315-318.
40. Pugh S, Thomas GOA. Patients with adenomatous polyps and carcinomas have increased colonie mucosal prostaglandin E2. Gut 1994; 35: 675-678.
41. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-523.
42. Narisawa T, Kusaka H, Yamazaki Y, et al. Relationship between prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 1990; 33: 840-845.
43. Craven PA, Saito R, DeRubertis FR. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 1983; 72: 1365-1375.
44. 2 suppresses the increases in the proliferative activity of rat colonie epithelium induced by indomethacin and aspirin. Gastroenteralogy 1985; 89: 1054-1063.
45. Uribe A, Alam M, Midtvedt T. E2 prostaglandins modulate cell proliferation in the small intestinal epithelium of the rat. Digestion 1992; 52: 157-164.
46. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-998.
47. Alberts DS, Hixson L, Ahnen D, et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 1995; 22: 18-23.
48. Piazza GA, Rahm ALK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3110-3116.
49. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
50. Sheng GG, Shao J, Sheng H, et al. A selective cyclooxygenase 2 inhibitor suppressed the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997; 113: 1883-1891.
51. Marnett L. Generation of mutagens during arachidonic acid metabolism. Cancer Metast Rev 1994; 13: 303-308.
52. Goldberg Y, Dynlacht BD, Rigas B, Shiff SJ. Sulindac and sulindac sulfide alter the levels of pRb and p53 and the cyclin dependent kinase inhibitor p21 in HT-29 colon cancer cells. Gastroenterology 1995; 108: A475.
53. Winde G, Schmid KW, Brandt B, Müller O, Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenoniatous polyposis. Dis Colon Rectum 1991; 40: 1156-1169.
54. Phipps RP, Stein HG, Roper RL. A new view of prostaglandin E in the regulation of the immune response. Immunol Today 1994; 12: 349-352.
55. Beun GDM, van de Velde CJH, Feuren GJ. T-cell based cancer immunotherapy; directed or indirecled tumour-cell recognition. Immunol Today 1994; 15: 11-15.
56. Nolan RD, Danilowicz RM, ElingTE. Role of arachidonic acid metabolism in mitogenic response of BALB/c 3T3 fibroblasls to epidermal growth factor. Mol Pharmacol 1988; 33: 650-656.
57. Hla T, Ristimäki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann NY Acad Sci 1993; 696: 197-204.
58. Klein WA, Miller HH, Anderson M, Decosse JJ. The use of indomethacin, sulindac and lamoxifen for the treatment of desmoid tumours associated with familial polyposis. Cancer 1987; 60: 2863-2868.